Risk-adapted Donor Lymphocyte Infusion Based on Chimerism and Donor Source in Pediatric Leukemia

Overview

Journal Blood Cancer J

Date 2013 Sep 3

PMID 23995046

Citations 12

Authors

P Rujkijyanont

C Morris

G Kang

K Gan

C Hartford

B Triplett

M Dallas

A Srinivasan

D Shook

A Pillai

C-H Pui

W Leung

Affiliations

Soon will be listed here.

Abstract

Donor lymphocyte infusion (DLI) is commonly used to treat leukemia relapse following stem cell transplantation. In florid relapse, however, the efficacy of DLI is limited with substantial risk of severe graft-versus-host disease (GvHD). Here, we develop a novel risk-adapted strategy characterized by pre-emptive DLI initiated at the time of mixed chimerism, a small starting dose based on donor source, dose-escalation guided by real-time chimerism monitoring and withholding of DLI immediately in patients achieving full donor chimerism. A total of 178 DLIs were given to 38 patients with mixed chimerism; thereafter, 33 patients (86.8%) had donor chimerism successfully increased, including 30 (78.9%) who had chimerism fully converted back to 100% donor. Cumulative incidence of relapse was significantly lower (P=0.00004) and overall survival higher (P=0.0003) in patients with chimerism fully corrected as compared with those of patients whose chimerism remained mixed. Only 13.2% of the patients developed acute grade III-IV GvHD with no associated mortality. In conclusion, the risk-adapted DLI strategy is useful in minimizing the risk of childhood leukemia relapse, GvHD and death.

Citing Articles

Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis.

Stadler M, Venturini L, Bunting I, Dammann E, Weissinger E, Schwarzer A Front Oncol. 2022; 12:867356.

PMID: 36059667 PMC: 9428843. DOI: 10.3389/fonc.2022.867356.

Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.

Leotta S, Condorelli A, Sciortino R, Milone G, Bellofiore C, Garibaldi B J Clin Med. 2022; 11(1).

PMID: 35011994 PMC: 8745746. DOI: 10.3390/jcm11010253.

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.

Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M Bone Marrow Transplant. 2021; 57(2):215-223.

PMID: 34750562 PMC: 8821014. DOI: 10.1038/s41409-021-01515-3.

Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.

Tsirigotis P, Gkirkas K, Kitsiou V, Chondropoulos S, Athanassiades T, Thomopoulos T Cancers (Basel). 2021; 13(11).

PMID: 34070786 PMC: 8198731. DOI: 10.3390/cancers13112699.

Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS.

Sharma A, Li Y, Huang S, Talleur A, Suliman A, Qudeimat A Bone Marrow Transplant. 2021; 56(8):1866-1875.

PMID: 33742153 DOI: 10.1038/s41409-021-01267-0.

References

Rettinger E, Willasch A, Kreyenberg H, Borkhardt A, Holter W, Kremens B . Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood. 2011; 118(20):5681-8. DOI: 10.1182/blood-2011-04-348805. View

Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J . NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010; 16(11):1467-503. PMC: 2955517. DOI: 10.1016/j.bbmt.2010.08.001. View

Pavletic S, Kumar S, Mohty M, de Lima M, Foran J, Pasquini M . NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell.... Biol Blood Marrow Transplant. 2010; 16(7):871-90. PMC: 2916039. DOI: 10.1016/j.bbmt.2010.04.004. View

Srinivasan A, Wang C, Srivastava D, Burnette K, Shenep J, Leung W . Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 19(1):94-101. PMC: 3554248. DOI: 10.1016/j.bbmt.2012.08.012. View

Levine J, Barrett A, Zhang M, Arora M, Pulsipher M, Bunin N . Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 2008; 42(3):201-5. DOI: 10.1038/bmt.2008.135. View

Miller J, Warren E, van den Brink M, Ritz J, Shlomchik W, Murphy W . NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic.... Biol Blood Marrow Transplant. 2010; 16(5):565-86. PMC: 2858433. DOI: 10.1016/j.bbmt.2010.02.005. View

Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D . Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant. 2004; 33(8):815-21. DOI: 10.1038/sj.bmt.1704444. View

Alyea E, DeAngelo D, Moldrem J, Pagel J, Przepiorka D, Sadelin M . NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic.... Biol Blood Marrow Transplant. 2010; 16(8):1037-69. PMC: 3235046. DOI: 10.1016/j.bbmt.2010.05.005. View

Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F . Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995; 86(4):1261-8. View

10.

Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K . High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011; 118(2):223-30. PMC: 3138677. DOI: 10.1182/blood-2011-01-333070. View

11.

Levine J, Braun T, Penza S, Beatty P, Cornetta K, Martino R . Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002; 20(2):405-12. DOI: 10.1200/JCO.2002.20.2.405. View

12.

Giralt S, Hester J, Huh Y, Rondon G, Seong D, Lee M . CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995; 86(11):4337-43. View

13.

Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P . Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol. 2004; 22(9):1696-705. DOI: 10.1200/JCO.2004.05.198. View

14.

Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R . The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia. 2012; 26(8):1821-8. DOI: 10.1038/leu.2012.66. View

15.

Yan C, Liu D, Liu K, Xu L, Liu Y, Chen H . Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012; 119(14):3256-62. DOI: 10.1182/blood-2011-09-380386. View

16.

Breuer S, Rauch M, Matthes-Martin S, Lion T . Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther. 2012; 16(2):63-77. DOI: 10.1007/BF03256431. View

17.

Pulsipher M, Bader P, Klingebiel T, Cooper L . Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009; 15(1 Suppl):62-71. DOI: 10.1016/j.bbmt.2008.11.009. View

18.

Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P, Duffner U . Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia. 2005; 19(6):971-7. DOI: 10.1038/sj.leu.2403721. View

19.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

20.

Kroger N, Bacher U, Bader P, Bottcher S, Borowitz M, Dreger P . NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following.... Biol Blood Marrow Transplant. 2010; 16(9):1187-211. PMC: 7272718. DOI: 10.1016/j.bbmt.2010.06.008. View